ASCO 2022: Real-World Data on Maintenance Olaparib in BRCA-Mutated Ovarian Cancer
Posted: 07/01/2022 | By: Justine Landin, PhD

In the phase III SOLO-1 trial, first-line treatment with the PARP inhibitor olaparib extended progression-free survival among patients with BRCA-mutated ovarian cancer. In a study presented at the 2022 ASCO Annual Meeting, Eskander et al evaluated real-world characteristics, treatment patterns, and outcomes among patients with newly diagnosed, BRCA-mutated ovarian cancer receiving treatment with olaparib.

Question 1 of 5

Which type of first-line therapy is associated with a 70% relapse rate within 3 years for patients with newly diagnosed ovarian cancer?

Choose 1